A report of the article titled Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Denosumab an alternative option to zoledronic acid for SRE prevention in multiple myeloma
Comments
User Name